ABSTRACT
The farnesyltransferase inhibitor lonafarnib reduces tau inclusion burden and atrophy in familial tauopathy models by inhibiting farnesylation on the Ras GTPase, Rhes, and activating autophagy. While hinting at a role of Rhes in tau aggregation, it is unclear how translatable these results are for sporadic forms of tauopathy. We used a combination of quantitative pathology using multiplex immunofluorescence for Rhes, several tau post-translational modifications, and single nucleus RNA sequence analysis to interrogate Rhes presence and distribution in human cortical neurons and Rhes relation to tau and TDP-43 changes. snRNA data suggest that Rhes is found in all cortical neuron subpopulations, not only in striatum cells. Histologic investigation in hippocampal formation from multiple postmortem cases in five different tauopathies and healthy controls and TDP-43 proteinopathy showed that nearly all neurons in control brains display a pattern of diffuse cytoplasmic Rhes positivity. However, in the presence of abnormal tau, but not TDP-43 inclusions, the patterns of neuronal cytoplasmic Rhes tend to present as either punctiform or fully absent. Our findings reinforce the relevance of the link between Rhes changes and tau pathology suggested by in vivo and in vitro models of tauopathy and support a potential clinical application of lonafarnib to tauopathies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by National Institute on Aging grants K24AG053435, K08AG052648, R01AG062359, F30AG066418 and R56AG057528 as well as National Institute of Neurological Disorders and Stroke grant U54NS100717-04 with additional support from Institutional grants NIH P30 AG062422 and P01AG019724, the Rainwater Charitable Foundation, and the Larry L. Hillblom Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was considered non-human by UCSF IRB because it only contains postmortem human brain tissue from de-identified cases
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw data is available upon request
